BBLG Stock — Bone Biologics Corp

Bone Biologics Corp (BBLG)

Updated October 16, 2026.

BBLG is a Stock. Total return is -90.4% over the past 10.5 years, 429.7 points behind SPY at 339.3%.

Bone Biologics Corporation is a medical device company focused on bone regeneration products for spinal fusion and other orthopedic applications. Its lead product candidate is NELL-1/DBM, a recombinant protein designed to promote bone growth in spinal fusion procedures, with additional development underway for trauma and osteoporosis indications. The company does not currently distribute dividends and is oriented toward investors seeking potential capital appreciation rather than income.

BBLG performance versus SPY

Price and return data through 2026-10-16.

Total return is -90.4% over the past 10.5 years, 429.7 points behind SPY at 339.3%. Over the past year its total return — price change plus distributions reinvested — is -84.6%. Its deepest 1-year drawdown was 84.9%.

BBLG key facts

Asset type

Stock

Asset class

Equity

Inception date

03/31/2016

Distribution frequency

None

Last close

$0.40 (as of 2026-10-16)

Market cap

$1,088,643

Average volume

59748.0

Payment date

07/24/2018

Beta

0.574

Payout ratio

0.0%

EPS

$-1.37

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BBLG risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 84.9%.

Who may consider BBLG — and who may not

It is a weaker fit for investors who need monthly cash flow (BBLG does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BBLG

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions